MTX-001
Venous Leg Ulcers (Chronic Wound Healing)
Phase 2Active
Key Facts
Indication
Venous Leg Ulcers (Chronic Wound Healing)
Phase
Phase 2
Status
Active
Company
About Merakris Therapeutics
Merakris Therapeutics, founded in 2015 and based in Durham, NC, is an emerging leader in regenerative medicine with a unique focus on cell-free therapeutics. The company leverages cell-derived proteins and extracellular matrix technology to develop products for advanced wound care and ophthalmology. Its lead investigational drug, MTX-001, is in clinical development following positive FDA interactions, positioning Merakris to address significant unmet needs in chronic wound healing. The company operates as a private, science-led organization advancing both commercial products and a robust clinical pipeline.
View full company profile